Literature DB >> 6863928

Binding of cyclosporine by human lymphocytes and phospholipid vesicles.

S J LeGrue, A W Friedman, B D Kahan.   

Abstract

The purpose of this investigation was to identify and characterize a possible plasma membrane receptor for cyclosporine (CsA) on human lymphoid cells. Binding of 3H-CsA by normal human lymphocytes and purified lymphoid subpopulations was examined using ligand concentrations ranging from 5 X 10(-7) to 10(-10) M. Specificity was determined using a 500-fold excess of unlabeled drug. No differences were observed in the uptake of 3H-CsA by B cells or T cells using Cartesian or semilogarithmic analyses. Scatchard analysis of the specific binding of CsA by normal peripheral blood lymphocytes yielded two dissociation constants: a high affinity site with a KD of 2 to 6 X 10(-9) M and a low affinity site with a KD of about 10(-7) M CsA. Scatchard analysis of specific CsA uptake by purified splenic T cells and B cells showed both populations to exhibit a low affinity site (KD = 3 to 6 X 10(-7) M and 5 to 8 X 10(-7) M, respectively), whereas only B cells bore a high affinity site (KD = 2 X 10(-9) M). Analysis of specific CsA uptake by cultured human kidney cells and phospholipid vesicles (1:1 molar ratio of phosphatidylcholine:cholesterol) showed both these targets to display a single, low affinity binding site (KD = 1 X 10(-7) M and 2 X 10(-8) M, respectively). The relevance of the low affinity site to CsA-mediated in vitro immunosuppression was suggested by the need for 10(-7) M CsA to achieve 50% suppression of lymphoproliferation during mixed lymphocyte culture. Taken together, these data argue against the existence of a specific CsA receptor on the surface of human T cells. Although a role for the high affinity B cell receptor in some types of CsA-induced immunomodulation cannot be excluded, the present study suggests that immunosuppression is achieved by the partitioning of the hydrophobic CsA molecule into the membrane lipid bilayer, thereby perturbing homeostatic control of membrane function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6863928

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 2.  Cardiac transplantation. Selection, immunosuppression, and survival.

Authors:  L W Stevenson; H Laks; P I Terasaki; B D Kahan; D C Drinkwater
Journal:  West J Med       Date:  1988-11

3.  FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes.

Authors:  V Warty; W Diven; E Cadoff; S Todo; T Starzl; A Sanghvi
Journal:  Transplantation       Date:  1988-09       Impact factor: 4.939

Review 4.  Complications of cyclosporin therapy.

Authors:  B D Kahan; S M Flechner; M I Lorber; C Jensen; D Golden; C T Van Buren
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

5.  Topical cyclosporin A in nickel contact hypersensitivity: results of a preliminary clinical and immunohistochemical investigation.

Authors:  R D Aldridge; H F Sewell; G King; A W Thomson
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

Review 6.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

7.  Cyclosporine does not inhibit mitogen-induced inositol phospholipid degradation in mouse lymphocytes.

Authors:  M K Bijsterbosch; G G Klaus
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

Review 8.  Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor.

Authors:  G N Gaulton; J F Markmann
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

9.  Physical characterization of cyclosporine binding sites in lymphocytes.

Authors:  C D Niebylski; H R Petty
Journal:  Biophys J       Date:  1993-03       Impact factor: 4.033

Review 10.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.